Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
about
Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma.Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: A case report.Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levelsUpdate on second primary malignancies in multiple myeloma: a focused review.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Second primary malignancies in multiple myeloma: an overview and IMWG consensus.Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study.Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases.Guidelines for screening and management of late and long-term consequences of myeloma and its treatment.Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.
P2860
Q36438206-EB994B9E-AAF6-4714-B1DF-C736AA36D93EQ37108758-E3DBD908-9BA1-47B9-8221-05A5337F46FCQ37282307-95F9A4AB-AC09-4900-A182-EBA4A74267C5Q37325843-4B9F4225-0A91-41D3-8EEB-53BB3BC27152Q38178031-E00436DC-9ECC-4C83-8962-F36ED2B17F3AQ38462720-FD932E5D-6CDA-4106-95A4-E8EB2679E0FFQ39013620-897D57BC-1F25-4E9F-9219-8714970E86EBQ39033552-AAB18634-0630-48BF-A411-0A80B857DE0EQ40705509-8BCA3996-3FB8-48BF-8A8D-72AF02FCE414Q44449693-EEE4BBCE-4192-4460-8FB0-F3BE2B8A5F04Q46557542-A1F94BF7-535A-4F7A-B104-F964A527A214Q47587127-401C5CA6-51A5-4DB2-8FA4-CB44B19EB536Q54710993-81600B54-4F18-4F13-8BE6-3A2810F18C2F
P2860
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term outcome with lenalid ...... ly diagnosed multiple myeloma.
@en
Long-term outcome with lenalid ...... ly diagnosed multiple myeloma.
@nl
type
label
Long-term outcome with lenalid ...... ly diagnosed multiple myeloma.
@en
Long-term outcome with lenalid ...... ly diagnosed multiple myeloma.
@nl
prefLabel
Long-term outcome with lenalid ...... ly diagnosed multiple myeloma.
@en
Long-term outcome with lenalid ...... ly diagnosed multiple myeloma.
@nl
P2093
P2860
P356
P1433
P1476
Long-term outcome with lenalid ...... wly diagnosed multiple myeloma
@en
P2093
G Srivastava
S R Hayman
P2860
P2888
P304
P356
10.1038/LEU.2013.143
P577
2013-05-07T00:00:00Z